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Abstract 
PROBLEM: To add to diversity in our state biobank, we explored the feasibility of collecting 
genetic material from adolescents with Oppositional Defiant Disorder (ODD) and/or Conduct 
Disorder (CD) and their family members. We also preliminarily explored genetic factors 
associated with ODD and/or CD by comparing participant data to 1000 Genome Project data on 
minor allele frequencies.  
METHODS: Adolescents with ODD and/or CD and family members provided saliva samples for 
genetic testing. We evaluated five single nucleotide polymorphisms (SNPs), respectively in the 
dopamine receptor subtype D2, dopamine receptor subtype D3, dopamine beta-hydroxylase, 
dopamine transporter gene SLC6A3, and alpha-2-adrenergic receptor genes. Fisher’s exact tests 
were used to examine differences in minor allele frequencies for each SNP.  
FINDINGS: 31 viable samples were genotyped from 15 affected adolescents and 16 unaffected 
family members; the 60% consent rate reflected high feasibility. Compared to the 1000 Genome 
Project frequencies, affected adolescents had higher frequencies of the genetic variant in the 
dopamine receptor subtype D2 (p=0.05) and dopamine beta-hydroxylase (p=0.03), but not of the 
other three SNPs examined.  
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CONCLUSIONS: Collecting genetic materials from an ethnically diverse sample of affected 
adolescents and their families is feasible. We offer practical suggestions to strengthen the 
integrity of future research studies. 
Key words: precision medicine, genetic variants, saliva samples 
As a psychiatric mental health nurse in child and adolescent nursing, imagine having a 
tool that helps pinpoint your patients’ diagnoses and the gene variants associated with their 
phenotypic or symptom presentations (Beachy, Olson, & Berger, 2015). That is the promise that 
precision medicine or precision health holds for all Americans. But this promise will never be 
realized without large data sets of biological or genetic information from large cohorts of 
volunteer patients and individuals (Collins, 2015; National Institutes of Health [NIH], 2015), 
including those with mental health disorders who are diverse in age, gender, race, ethnicity, and 
other characteristics.  
To add to the diversity in our state biobank, we explored the feasibility of collecting 
genetic material from adolescents with Oppositional Defiant Disorders (ODD) and/or Conduct 
Disorder (CD) (American Psychiatric Association [APA], 2013) and their family members. We 
added a sample collection arm to a small descriptive study focused on understanding needs of 
families of adolescents with ODD and/or CD. Since we had data on hand, albeit a small amount, 
we also explored genetic factors associated with ODD and/or CD by comparing saliva samples 
of affected adolescents and unaffected family members (e.g., parents, siblings) to the 1000 
Genome Project minor allele frequencies (Durbin et al., 2010). The minor allele frequency is the 
frequency with which the least common allele occurs in a given population. This least common 
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allele is known as the variant, and though expressing the variant may have no downstream 
effects, it can also cause a variety of phenotypic changes. These changes could include 
increasing the risk of developing a particular disorder, affecting the severity with which the 
disorder occurs, or altering the rate of metabolism of a specific medication. 
Genetic variants are important to ODD and/or CD. Single nucleotide polymorphisms 
(SNPs) are a common type of genetic variation that occur when there is a change in a single 
nucleotide of the deoxyribonucleic acid (DNA) sequence. DNA is the genetic material inherited 
from parents. Studies, including seminal works by Comings and colleagues (1996; 2000a; 
2000b), have identified five SNPs relevant to persons with ODD and/or CD (Beaver et al., 2007; 
Kopecková et al., 2008; Lee et al., 2007).  Four of these SNPs are in the dopaminergic gene 
family: dopamine receptor subtype D2 (DRD2, rs1800497), dopamine receptor subtype D3 
(DRD3, rs6280), dopamine beta-hydroxylase (DBH, rs1108580), and the dopamine transporter 
(DAT1) gene SLC6A3 (rs27072). The fifth SNP is for the alpha-2-adrenergic receptor gene 
(ADRA2A, rs18005544). These genes are also thought to be involved in the etiology of Attention 
Deficit Hyperactivity Disorder, which often co-occurs with ODD and/or CD (Johnson, 2015).  
Methods 
This focused genetic association study was part of a descriptive study of 52 individuals 
from 15 families of adolescents with ODD and/or CD that has been described in detail elsewhere 
(Oruche et al., 2014). All study protocols were approved by the university institutional review 
board. We obtained parental consent for themselves and their children as well as children’s 
assents to obtain 10 ml saliva samples to obtain DNA for future investigation such as: (1) 
determining how the body breaks down medicines, how medicines are carried through the body, 
or how well they work in adolescents with ODD and/or CD; and (2) evaluating inherited risk of 
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developing emotional problems in family members (i.e., siblings and parents) of affected 
adolescents. We also explained that the DNA would not be used for anything other than the 
specified uses without the participants’ written agreement. Participants received no 
compensation for the optional genomic study.  
 
 
Sample Collection and Processing 
For each subject, the 10 ml saliva sample was collected into an Oragene®•DNA saliva 
collection cup (DNA Genotek Inc., Kanata, Ontario, Canada). Research staff sealed the cup to 
prevent evaporation and labeled it with the participant identification number. The samples were 
transported to the laboratory for storage and processing.  DNA was isolated from the saliva 
samples using the manufacturer-supplied protocol (DNA Genotek Inc, 2015). The concentration 
of double-stranded DNA was quantified using the reagents and protocol for the Quant-iT Broad 
Range Assay Kit and the Qubit Fluorometer (Invitrogen, Carlsbad, California). The DNA 
samples were then transferred into de-identified cryovials and stored at −80°C in secure freezers 
until genotyping was performed.  
SNP genotyping was performed using all reagents and predesigned primers available 
from Life Technologies (Thermo Fisher Scientific Inc., Waltham, Massachusetts) in combination 
with Taqman Real-Time polymerase chain reaction assays. 5µL of 2ng/µL DNA for each sample 
was added to each SNP primer and Taqman Genotyping Master Mix as directed by the 
manufacturer’s published methods.  No-template negative controls and a 10% quality control 
sampling were run on each plate.  The polymerase chain reactions were run on a QuantStudio 
12K Flex RT-PCR System by Life Technologies/Thermo Fisher Scientific Inc. 
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Statistical Analysis 
Feasibility was evaluated based on consent rates. Fisher’s exact tests were used to 
evaluate differences in minor allele frequencies of each tested SNP in the affected adolescents’ 
samples and the family samples compared to the 1000 Genome Project. A p-value of < 0.05 was 
considered significant. Results were not corrected for multiple comparisons in this pilot analysis. 
Analyses were performed in the statistical software R version 3.1.1.  
Results  
Of the 52 possible participants, 31 viable samples were genotyped: 15 from affected 
adolescents and 16 from unaffected family members. This consent rate of 60% was sufficient to 
judge the process of obtaining saliva in this population feasible. Adolescents were a mean age of 
13.7 ± 1.8 years, mostly male (66.7%), and mostly multiracial (46.7%) or African American 
(33.3%).  Family members were biological or blood relatives including parents, grandparents, 
and siblings. They were a mean age of 36.8 ± 15.9 years old, mostly female (75%), and African 
American (62.5%) or Caucasian (32.3%). Clinical diagnoses are shown in Table 1.   
As shown in Table 2, adolescents with ODD and/or CD had significantly higher minor 
allele frequencies for SNPs in DRD2 and DBH compared to the 1000 Genome Project sample. 
Family members’ minor allele frequency expression did not significantly differ from those in the 
1000 Genome Project.  
 Discussion 
Successful gathering of the genomic data in this project required collaboration between 
mental health researchers and genomic experts. We showed the feasibility of collecting genetic 
materials from an ethnically diverse sample of adolescents with ODD and/or CD and their 
families. Our findings reinforce the seminal work by Comings and his colleagues (2000a; 2000b) 
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focused on the association of the DRD2 and DBH gene variants in children with ODD and/or 
CD. Our study is important in its inclusion of a relatively large sample of African American and 
multiracial adolescents with mental disorders and their family members. Inclusion of diverse 
populations is significant because we want to make sure that all persons, even those considered 
relatively vulnerable or with mental disorders, have the opportunity to contribute and benefit 
from genome-wide association studies (NIH, 2015; Oruche, Carpenter, Renbarger, & Ross, 
2016).  
Although our feasibility study was limited by its small sample size, we learned valuable 
lessons and offer practical suggestions to strengthen the integrity of future research studies in 
three areas. First, in regard to informed consent, we anticipated that some participants would opt 
not to participate in the optional genomic study. But we did not clearly address their concerns 
regarding the privacy and security of data (Oruche et al., 2016). Guidelines for consenting are 
now available for researchers and should be used in the future (NIH, 2015). Researchers need to 
provide written and verbal information about privacy and confidentiality, research questions to 
be explored, and participants’ access to the results if they wish to use them in informing their 
own treatment choices in the future.  
Second, we encountered the common challenge in genomic studies of the validity and 
reliability of phenotypic data. For example, medical records documenting mental or psychiatric 
diagnoses would have been more valid and reliable than self-reported diagnoses. Family 
members of adolescents with ODD and/or CD have a high probability of carrying the gene in 
question and having no symptoms. For our study, adolescents’ diagnoses were confirmed by 
medical records but family members self-reported their psychiatric diagnoses. This means that 
some family members may have been affected with ODD and/or CD. Likewise, the 1000 
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Genome Project samples are not associated with phenotypic data so some persons in these 
samples could have had ODD and/or CD.  In sum, phenotypic data are critically important in 
genomic studies for confidence and meaningful interpretation of study findings. Future research 
must collect phenotype data, ideally using standardized diagnostic tools. 
Third, we lost some saliva samples because of inadequate quantity, the saliva did not mix 
well with the reagents, or lids of the collection cup were not tightly sealed and so the sample 
dried up. Proper training for research staff and clear instructions for volunteer participants are 
critical to collecting viable samples for data analyses.  
In conclusion, our hope is that this brief report will serve as encouragement to other 
psychiatric-mental health nurses to assist with the collection, analysis, and interpretation of 
biological data, which will contribute to realizing the promise of precision health care.  
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